{"id":"W4288969861","doi":"10.1016/j.jtocrr.2022.100385","title":"Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; EMD Serono; Otsuka America; Ribon Therapeutics; Takeda Oncology; Mirati Therapeutics; Bayer Fund; Abbott Laboratories; Clovis Oncology; National Center for Advancing Translational Sciences; Johnson and Johnson; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Ipsen Biopharmaceuticals; Novartis; Celgene; Unum Therapeutics; Merck KGaA; Servier; Gilead Sciences; Sanofi; Roche; Yuhan; Merck; GlaxoSmithKline; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Canadian Asian Studies Association; AstraZeneca; Aerie Pharmaceuticals; Pfizer; Ariad Pharmaceuticals; Boehringer Ingelheim; Amgen; Regeneron Pharmaceuticals","keywords":"Crizotinib; Refractory (planetary science); Medicine; Phase (matter); Term (time); Internal medicine; Oncology; Phases of clinical research; Clinical trial; Lung cancer; Materials science; Chemistry; Physics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007367743,0.0008714258,0.001265297,0.0003064093,0.0004211895,0.001287741,0.0006527838,0.0008138524,0.001975172],"category_scores_gemma":[0.003448289,0.0003172697,0.001523748,0.0004357188,0.0005482268,0.0007653543,0.0003237024,0.001788879,0.0004455749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001051447,"about_ca_system_score_gemma":0.001100769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009526387,"about_ca_topic_score_gemma":0.002689163,"domain_scores_codex":[0.9982283,0.0011136,0.0001582723,0.0001525069,0.0001994647,0.0001479974],"domain_scores_gemma":[0.9974985,0.0006410815,0.001040666,0.0001637713,0.0002807083,0.0003752111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.677507,0.008391108,0.0310702,0.002837934,0.007466805,0.0002402843,0.0002678424,0.002106744,0.02479923,0.0003784178,0.01042984,0.2345046],"study_design_scores_gemma":[0.5802806,0.2555479,0.1166198,0.0006170815,0.008597289,0.001002806,0.0001640727,0.001475465,0.01111945,0.0007817338,0.02363191,0.0001620783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9135605,0.07596844,0.0007542682,0.00191267,0.0002517009,0.0008534036,0.003001581,0.0001085898,0.003589013],"genre_scores_gemma":[0.9751764,0.01545528,0.001196137,0.001637638,0.0004307836,0.0006466794,0.004224336,0.00002958679,0.001203047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007367743,"threshold_uncertainty_score":0.03896481,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2062120733192719,"score_gpt":0.5581480541043659,"score_spread":0.351935980785094,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}